Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Increases Antioxidative Capacity and Improves Renal Function in Diabetic Rats.

Yaribeygi, Habib; Hemmati, Mohammad Amin; Nasimi, Fatemeh; Maleki, Mina; Jamialahmadi, Tannaz; Reiner, Ivan; Reiner, Zeljko; Sahebkar, Amirhossein

Yaribeygi, Habib; Hemmati, Mohammad Amin; Nasimi, Fatemeh; Maleki, Mina; Jamialahmadi, Tannaz; Reiner, Ivan; Reiner, Zeljko; Sahebkar, Amirhossein.

Afiliación

Yaribeygi H; Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran.
Hemmati MA; Student Research Committee, Semnan University of Medical Sciences, Semnan, Iran.
Nasimi F; Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran.
Maleki M; Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Jamialahmadi T; Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Reiner I; School of Nursing, Catholic University of Croatia, 10000 Zagreb, Croatia.
Reiner Z; Department of Internal Medicine, University Hospital Center Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia.
Sahebkar A; Polish Mother's Memorial Hospital Research Institute, 93-338 Lodz, Poland.

J Clin Med ; 12(11)2023 Jun 01.

Article en En | MEDLINE | ID: mdl-37298010

Palabras clave

SGLT2 inhibitor; diabetes mellitus; diabetic nephropathy; empagliflozin; malondialdehyde; oxidative stress

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Clin Med Año: 2023 Tipo del documento: Article País de afiliación: Irán